Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

B cell CD19 is widely transferred between immune cells [M]

ABSTRACT: When immune cells interact, they frequently exchange membrane-bound antigens. Our evolving understanding of these processes challenges the cellular specificity of lineage markers and therapeutically applied monoclonal antibodies. We here report that CD19, an assumingly exclusive B cell marker, is transferred via trogocytosis when B cells activate T cells as antigen-presenting cells. In a B cell-driven model of experimental autoimmune encephalomyelitis, CD19+ T cells accordingly expanded and showed enhanced features of activation, differentiation, and encephalitogenicity. A similar profile of augmented pathogenic properties of CD19+ T cells was detected in patients with chronic CNS demyelination. Here, CD19+ T cells were found to be concomitantly depleted by inebilizumab, an approved anti-CD19 antibody, which may support its effectiveness. Furthermore, we report that CD19 is found on myeloid cells after phagocytosis of apoptotic B cells. These results highlight the commonness of membrane and antigen transfer between interacting cells and provide instrumental considerations for monoclonal antibody therapies.

ORGANISM(S): Mus musculus

PROVIDER: GSE286404 | GEO | 2026/06/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

B cell CD19 is widely transferred between immune cells [CD11b+]

Project description:When immune cells interact, they frequently exchange membrane-bound antigens. Our evolving understanding of these processes challenges the cellular specificity of lineage markers and therapeutically applied monoclonal antibodies. We here report that CD19, an assumingly exclusive B cell marker, is transferred via trogocytosis when B cells activate T cells as antigen-presenting cells. In a B cell-driven model of experimental autoimmune encephalomyelitis, CD19+ T cells accordingly expanded and showed enhanced features of activation, differentiation, and encephalitogenicity. A similar profile of augmented pathogenic properties of CD19+ T cells was detected in patients with chronic CNS demyelination. Here, CD19+ T cells were found to be concomitantly depleted by inebilizumab, an approved anti-CD19 antibody, which may support its effectiveness. Furthermore, we report that CD19 is found on myeloid cells after phagocytosis of apoptotic B cells. These results highlight the commonness of membrane and antigen transfer between interacting cells and provide instrumental considerations for monoclonal antibody therapies.

2026-06-03 | GSE286403 | GEO

Transfer of antigen target into CAR T cells via trogocytosis

Project description:To characterize transfer of molecules from target cells into CAR T cells via trogocytosis we cultured NALM-6 leukemia cell line expressing a CD19-mCherry fusion protein with CAR T cells. NALM6-CD19-mCherry were loaded with heavy amino acid and cocultured with CAR T cells for 1 hour. CAR T cells were next sorted into two fractions, mCherry-positive (TrogPos), and -negative (TrogNeg). Proteomics analysis revealed the presence of targeted antigen (CD19) in the TrogPos only.

2019-03-29 | PXD012833 | Pride

B cell CD19 is widely transferred between immune cells [M]

Project description:B cell CD19 is widely transferred between immune cells [M]

| PRJNA1209078 | ENA

B cell CD19 is widely transferred between immune cells [CD11b+]

Project description:B cell CD19 is widely transferred between immune cells [CD11b+]

| PRJNA1209079 | ENA

Human RP105 monoclonal antibody enables the production of antigen-specific antibody

Project description:Human RP105 monoclonal antibody enables the production of antigen-specific antibody

| PRJNA1006628 | ENA

naive T vs conA treated sample

Project description:Although T cell activation is closely linked to internalization of the T cell antigen receptor (TCR), relatively few studies have examined the release of TCRs via shedding of T cell microvilli following physical interaction with cognate antigen-presenting cells. In this study, we investigated the physiological implications of the release of TCRs and other external membrane components. We term this event “trogocytic molting”, as it occurs through a combined process of trogocytosis and enzymatic vesiculation of microvillar membrane structures. Surprisingly, in contrast to TCR internalization, this event leads to rapid upregulation of surface TCRs and remarkable metabolic reprogramming of cholesterol and fatty acids synthesis to meet the demands of clonal expansion, which drives multiple rounds of division and cell survival. These findings suggest that, contrary to the long-standing paradigm that emphasizes the importance of TCR internalization, external membrane loss, including TCRs, is a significant mechanism for clonal expansion

2023-05-01 | GSE228654 | GEO

Prediction of Horizontally and Widely Transferred Genes in Prokaryotes.

Project description: Not available

| S-EPMC6287321 | biostudies-literature

naive T vs imm_sol Ab treated and LatA treated

2023-05-01 | GSE228653 | GEO

Selective Elimination of Immunosuppressive T cells in Patients with Multiple Myeloma

Project description:Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed on immunosuppressive CD8+CD28-CD57+ Tregs in multiple myeloma (MM). SLAMF7 expression associated with T cell exhaustion surface markers and exhaustion-related transcription factor signatures. T cells from patients with a high frequency of SLAMF7+CD8+ T cells exhibited decreased immunoreactivity towards the MART-1aa26Ã¢Â€Â“35*A27L antigen. A monoclonal anti-SLAMF7 antibody (elotuzumab) specifically depleted SLAMF7+CD8+ T cells in vitro and in vivo via macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Anti-SLAMF7 treatment of MM patients depleted suppressive T cells in peripheral blood. These data highlight SLAMF7 as a marker for suppressive CD8+ Treg and suggest that anti-SLAMF7 antibodies can be used to boost anti-tumoral immune responses in cancer patients.

| EGAS00001004915 | EGA

Epitope mapping of a monoclonal antibody directed against Neisserial Heparin Binding Antigen

Project description:Epitope mapping of a monoclonal antibody directed against Neisserial Heparin Binding Antigen

| PRJNA321411 | ENA